Rixathon Caution For Usage

Incompatibilities: No incompatibilities between RIXATHON and polyvinyl chloride or polyethylene bags or infusion sets have been observed.
Special precautions for disposal and other handling: RIXATHON is provided in sterile, preservative-free, non-pyrogenic, single use vials.
The product should be discarded if visible particle is observed before use.
Aseptic preparation: Aseptic handling must be ensured when preparing the infusion. Preparation should be: performed under aseptic conditions by trained personnel in accordance with good practice rules especially with respect to the aseptic preparation of parenteral products.
Prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents.
Aseptically withdraw the necessary amount of RIXATHON, and dilute to a calculated concentration of 1 to 4 mg/mL rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/mL (0.9%) solution for injection or 5% D-Glucose in water. For mixing the solution, gently invert the bag in order to avoid foaming. Care must be taken to ensure the sterility of prepared solutions. Since the medicinal product does not contain any anti-microbial preservative or bacteriostatic agents, aseptic technique must be observed. Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.